Dorota Weber

Dr. Dorota Weber

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
DWDorota Weber
Dorota Weber
RŁRobert Łuczyk
Robert Łuczyk
APAnna Pacian
Anna Pacian
TKTeresa Kulik
Teresa Kulik
Monika Baryła-MatejczukMonika Baryła-Matejczuk
Monika Baryła-Matejczuk
Background/Objectives: Vitamin D deficiency is commonly observed in patients with breast cancer and may affect disease course and treatment outcomes. The determinants of vitamin D status in this population remain incompletely understood, particularly with respect to lifestyle, psychosocial, and tumour-related factors. The aim of this study was to identify environmental and clinical factors associated with serum 25-hydroxyvitamin D [25(OH)D] concentrations in women with breast cancer, with particular emphasis on dietary patterns, psychological distress, sleep quality, and tumour molecular subtype. Methods: A cross-sectional observational study was conducted among 101 women with histopathologically confirmed invasive breast cancer, recruited at the St. John of Dukla Oncology Centre of the Lublin Region (COZL) in Lublin, Poland, between 2018 and 2019. Serum 25(OH)D concentrations were measured by electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics) within 2–8 weeks after surgical treatment. Clinical and lifestyle data were collected using standardised questionnaires and medical records. Dietary patterns were assessed with the KomPAN questionnaire (pro-healthy diet index pHDI-10 and non-healthy diet index nHDI-14). Psychological distress was measured with the Distress Thermometer. Multiple linear regression with backward stepwise elimination was applied to identify factors independently associated with of 25(OH)D concentration. Results: Insufficient vitamin D status (25(OH)D < 30 ng/mL) was found in 56.4% of participants. The multivariable regression model was statistically significant (F(6,92) = 15.298; p < 0.001), explaining 49.9% of the variance in 25(OH)D concentrations. Factors independently associated with lower 25(OH)D included higher BMI (b = −0.715; p = 0.005), sleep disturbances (b = −6.257; p = 0.020), higher psychological distress score (b = −2.263; p < 0.001), and luminal B versus luminal A subtype (b = −5.909; p = 0.025). A higher pro healthy diet index (pHDI-10) was independently associated with higher 25(OH)D (b = 0.245; p = 0.040). Conclusions: Vitamin D status in patients with breast cancer is shaped by complex interactions among modifiable lifestyle factors and tumour characteristics. Targeted interventions addressing diet quality, psychological well-being, sleep health, and weight management may improve vitamin D status in this population. The association between molecular subtype and 25(OH)D concentrations warrants further prospective investigation. These findings should be interpreted with caution, as vitamin D supplementation and direct measures of sun exposure—both established determinants of 25(OH)D—could not be included as covariates and may account, at least in part, for the associations reported.

23 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MŁMarta Łuczyk
Marta Łuczyk
RŁRobert Łuczyk
Robert Łuczyk
DWDorota Weber
Dorota Weber
KSKamil Sikora
Kamil Sikora
KTKarolina Weronika Tutak
Karolina Weronika Tutak
ACAnna Charuta
Anna Charuta
Background/Objectives: Preoperative nutritional status is a recognised determinant of postoperative outcomes, influencing wound healing, complication rates, and length of hospital stay. This study assessed nutritional risk among patients prepared for surgical treatment using the Nutritional Risk Screening 2002 (NRS 2002) tool and examined its association with sociodemographic characteristics, gastrointestinal symptoms, comorbidities, and malignancy diagnosis. Methods: A cross-sectional survey was conducted among 94 patients hospitalized on general/minimally invasive surgery and oncological surgery wards of a military clinical hospital in Lublin, Poland, between January and March 2025, using the NRS 2002 tool alongside a structured sociodemographic and clinical questionnaire. Normality was assessed using the Shapiro–Wilk test. Group comparisons used the Mann–Whitney U test for two groups and the Kruskal–Wallis H test for three or more groups, with post hoc pairwise comparisons where indicated; associations with age and treatment duration were assessed using Spearman’s rank correlation; and the association between malignancy diagnosis and nutritional risk category was assessed using the chi-square test with Cramér’s V. Analyses were performed in R 4.2.2/RStudio, with α set at 0.05. Results: Most patients (76.6%, n = 72; 95% confidence interval [CI]: 67.1–84.0%) showed no increased nutritional risk on the final NRS 2002 classification, while 23.4% (n = 22; 95% CI: 16.0–32.9%) had an indication for nutritional treatment. Nutritional risk score increased significantly with age (Spearman ρ = 0.633, p < 0.001), educational level (Kruskal–Wallis H(3) = 19.29, p < 0.001), marital status (H(3) = 17.70, p = 0.001), employment status (H(2) = 21.92, p < 0.001), and ward length of stay (H(3) = 36.18, p < 0.001). Nausea, vomiting, diarrhoea, and appetite loss were each associated with higher scores (all p ≤ 0.002), whereas heartburn was not. Hypertension, atherosclerosis, and chronic obstructive pulmonary disease were associated with elevated scores (p ≤ 0.045). The proportion meeting the nutritional-treatment threshold was numerically higher among patients with malignancy than among those without malignancy (32.6% vs. 15.7%), but this difference did not reach statistical significance (Pearson χ2(1) = 3.70, p = 0.054, Cramér’s V = 0.199). Analyses of admission mode and total illness duration were not statistically significant (p = 0.828 and p = 0.452, respectively). Conclusions: While most patients prepared for surgery had no increased nutritional risk according to NRS 2002, nearly one in four met the tool’s threshold for nutritional treatment. In exploratory unadjusted analyses, higher scores were observed among older, retired, widowed, and less-educated patients and among those reporting selected gastrointestinal symptoms or specific comorbidities. Patients with malignancy more often met the threshold for nutritional treatment, although this difference was not statistically significant in the present sample. These findings support systematic preoperative nutritional screening followed by further assessment of patients who screen positive, consistent with Enhanced Recovery After Surgery (ERAS) principles.

20 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DWDorota Weber
Dorota Weber
ASAndrzej Stanisławek
Andrzej Stanisławek
AIAnna Irzmańska-Hudziak
Anna Irzmańska-Hudziak
TKTeresa Kulik
Teresa Kulik
APAnna Pacian
Anna Pacian
RŁRobert Łuczyk
Robert Łuczyk
Background: Vitamin D deficiency has been implicated in breast cancer pathogenesis and prognosis. However, the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and molecular breast cancer subtypes remains incompletely understood. Methods: This cross-sectional study included 168 women (89 breast cancer patients, 79 healthy controls) from Poland. Serum 25(OH)D was measured by electrochemiluminescence immunoassay. Blood samples were collected year-round, with 54% obtained during winter/spring months (October–March). Molecular subtypes (luminal A, luminal B, HER2-enriched, triple-negative) were classified by immunohistochemistry. Results: Mean 25(OH)D was 30 ± 13 ng/mL, with 55% showing insufficiency (<30 ng/mL). No significant differences were observed between patients and controls (p = 0.93). A borderline non-significant trend was observed across molecular subtypes (p = 0.055). HER2-enriched tumors showed descriptively higher concentrations (37.6 ng/mL, 95% CI: 29.5–45.8) compared to luminal A (31.0 ng/mL), luminal B (26.4 ng/mL), and triple-negative (25.9 ng/mL). A significant subtype × season interaction was detected (p = 0.015), though interpretation is limited by the absence of a main seasonal effect (p = 0.64). Age (OR = 1.06, p = 0.023) and BMI (OR = 1.06, p = 0.090) predicted vitamin D deficiency. Conclusions: Vitamin D insufficiency is prevalent in breast cancer patients and healthy women. In this exploratory analysis with limited statistical power, no definitive associations between 25(OH)D and molecular subtype were established. The descriptive trend suggesting higher vitamin D in HER2-enriched tumors requires validation. Limitations: Small sample sizes (n = 11–35 per subtype) and post-surgical blood collection limit interpretation; findings require validation in larger cohorts.

Verified
Journal Article
Open access
PDF file
DWDorota Weber
Dorota Weber
RŁRobert Łuczyk
Robert Łuczyk
APAnna Pacian
Anna Pacian
TKTeresa Kulik
Teresa Kulik
Monika Baryła-MatejczukMonika Baryła-Matejczuk
Monika Baryła-Matejczuk
Ki-67 is a well-established nuclear biomarker of tumor cell proliferation with key importance for the molecular classification and prognostic stratification of breast cancer. This cross-sectional study included 101 women with histopathologically confirmed invasive breast cancer treated at the St. John of Dukla Oncology Center of the Lublin Region (COZL), Poland (2018–2019). Ki-67 expression was assessed immunohistochemically on formalin-fixed, paraffin-embedded tumor tissue, and independent predictors were identified using multiple linear regression. The median Ki-67 was 20% (IQR: 15–40%). Ki-67 differed significantly between molecular subtypes (Kruskal–Wallis test H = 16.122; p = 0.001; η2 = 0.138): Luminal A tumors had the lowest Ki-67 (median 18%), whereas the Luminal B, HER2-enriched, and Triple-negative subtypes showed higher values (median 30% each). Ki-67 was significantly lower in tumors expressing the estrogen receptor (p = 0.005) and progesterone receptor (p = 0.023). Because the Luminal A/B distinction incorporates a Ki-67 threshold by definition, a multivariable model excluding molecular subtype was fitted using ER, PR, HER2, menopausal status, age, BMI category, and 25(OH)D as candidate predictors. This model identified HER2 positivity (b = 11.26; p = 0.024) and postmenopausal status (b = 17.93; p = 0.017) as independent predictors of higher Ki-67, with a borderline inverse association for age (b = −0.65; p = 0.092); the model explained 10.1% of variance (R2 = 0.101; F(3,95) = 3.574; p = 0.017), and neither ER, PR, BMI, nor 25(OH)D were retained. Serum 25(OH)D concentration showed no meaningful association with Ki-67, either unadjusted (Spearman ρ = 0.035; p = 0.730) or when forced into the retained multivariable model regardless of significance (adjusted b = −0.032; 95% CI: −0.337–0.272; p = 0.834); no association was observed between circulating 25(OH)D and Ki-67 in this cohort, although indirect biological relationships cannot be excluded.

22 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DWDorota Weber
Dorota Weber
RŁRobert Łuczyk
Robert Łuczyk
APAnna Pacian
Anna Pacian
PBPatrycja Brus
Patrycja Brus
KSKamil Sikora
Kamil Sikora
ACAnna Charuta
Anna Charuta
Background/Objectives: Health self-assessment captures perceived physical and psychological well-being. This study described current and recalled pre-infection health ratings, persistent symptoms, and sociodemographic and clinical correlates among adults reporting previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: A cross-sectional survey of 120 adults was conducted at University Clinical Hospital No. 4 in Lublin, Poland, and online between January and April 2026. An author-designed questionnaire assessed sociodemographic and clinical characteristics, current and recalled pre-infection general health, and symptoms following coronavirus disease 2019 (COVID-19). The 30-item General Health Questionnaire (GHQ-30) assessed current psychological symptoms. Both general health ratings were obtained in the same survey. Bivariate analyses used non-parametric tests and chi-square tests, with p < 0.05 as the nominal significance threshold. Results: Very good health was reported by 44.2% when recalling pre-infection health and by 28.3% for current health. Current health ratings were associated with age, education, employment, financial situation, and reported disease severity (all p < 0.001). The most commonly reported current complaints were fatigue/weakness (30.8%), cognitive disturbances (‘brain fog’; 17.5%), and dyspnoea (16.7%). Mean normalised GHQ-30 domain scores were 37.1/100 for anxiety and depression, 39.0/100 for general functioning, and 30.5/100 for interpersonal relationships. Poorer financial situation and more COVID-19 hospitalisations showed small positive correlations with poorer GHQ-30 scores (R = 0.19–0.27). Vaccine dose count showed a small correlation with general functioning (R = 0.18; p = 0.045). Conclusions: Current health was rated less favourably than recalled pre-infection health in this sample. Recall bias, selection effects, and unmeasured or uncontrolled confounding prevent attribution of this difference to infection. The exploratory associations do not establish independent risk factors, clinical diagnoses, or population prevalence.

30 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RŁRobert Łuczyk
Robert Łuczyk
DWDorota Weber
Dorota Weber
MŁMarta Łuczyk
Marta Łuczyk
KSKamil Sikora
Kamil Sikora
ACAnna Charuta
Anna Charuta
Background/Objectives: A cancer diagnosis and its subsequent treatment constitute one of the most psychologically demanding experiences a patient can face, and decades of psycho-oncology research have documented an elevated burden of depression, anxiety, and related conditions in this population. Reported prevalence figures nonetheless vary enormously between studies—a 2011 meta-analysis by Mitchell and colleagues, for instance, arrived at pooled depression estimates roughly half those reported in some subsequent work—complicating clinical decisions about who should be screened and how intensively. The present narrative review with preliminary quantitative synthesis set out to chart this variability directly: to assemble a cross-section of the international literature on depression, anxiety, post-traumatic stress disorder (PTSD), insomnia, and suicidal ideation in oncology patients to quantify how far pooled estimates diverge from one another when treatment setting, tumour type, and assessment instrument are allowed to vary freely, and to lay the empirical groundwork for a subsequent, fully systematic review by the author group. Methods: Consistent with the exploratory aims stated above, eligible primary studies were located through web-based literature searching and citation chaining rather than exhaustive querying of bibliographic databases; the search was therefore not conducted, and is not reported, as a PRISMA 2020-compliant systematic review. Cross-sectional or baseline cohort studies reporting original prevalence figures for at least one of the five outcomes above, in patients with a histologically confirmed malignancy, including adult and paediatric/adolescent patients, who were undergoing or had completed treatment, using a named validated instrument, were retained. Where two or more studies addressed the same outcome, a random effects pooled proportion (DerSimonian–Laird estimator, Freeman–Tukey double arcsine variance stabilisation) was computed in Python as an illustrative, not definitive, summary statistic, alongside Cochran’s Q and I2. Results: Twelve studies conducted across nine countries were retained, contributing fourteen outcome-level data points. The illustrative pooled prevalence of depression was 45.6% (95% CI: 29.5–62.3%; k = 3; I2 = 91.2%) and of anxiety 44.1% (95% CI: 32.7–55.8%; k = 4; I2 = 90.5%)—both considerably above the double-digit figures reported in earlier interview-based meta-analyses, reflecting the self-report screening instruments and, in several instances, lower-income treatment settings represented in the present sample. Pooled PTSD prevalence was 17.0% (95% CI: 7.3–29.7%; k = 3; I2 = 91.8%) and pooled insomnia prevalence 38.0% (95% CI: 24.5–52.6%; k = 3; I2 = 86.7%). A single Chinese multicentre study of 509 women with advanced breast cancer reported suicidal ideation in 22.8% of respondents; this figure is reported descriptively only, is not pooled, and should not be extrapolated to oncology patients generally. Conclusions: Even acknowledging its exploratory character, this synthesis reinforces a conclusion already well established in psycho-oncology: a substantial minority, and on some metrics close to half, of patients receiving cancer treatment report clinically significant psychological symptoms, with figures highest for depression and anxiety in the self-report studies assembled here. The magnitude of between-study heterogeneity observed for every outcome, however, argues strongly against treating any single percentage—ours included—as a stable population estimate; tumour type, treatment phase, country income level, and instrument choice all plausibly move the figure by a considerable margin, and disentangling these influences is the explicit purpose of the fully systematic review the author group is now undertaking; the present figures should be read as hypothesis-generating inputs to that forthcoming systematic review, not as stand-alone prevalence estimates suitable for direct clinical or policy use.